Skip to main content

α-Galactosylceramide: Potential Immunomodulatory Activity and Future Application [General Articles]

Buy Article:

$63.00 plus tax (Refund Policy)

Abstract:

α-Galactosylceramide (α-GalCer), is a glycolipid which has been identified as a ligand recognized by a special group of immune T cells, known as invariant NKT cells. γ-GalCer can powerfully activate invariant NKT cells to produce immunoregulatory cytokines, including interferon-α and IL-4, and thereby exert a variety of subsequent effects on other cells in the immune system. Recent studies have revealed the mechanism of α- GalCer-induced iNKT cell-activation in immune responses to tumors and microbes, and in the suppression of autoimmune diseases. In this review, we discuss the potential immunomodulatory activity of α-GalCer and its possible future application for clinical studies in humans.

Keywords: GalCer; Galactosylceramide; immunomodulatory

Document Type: Review Article

DOI: https://doi.org/10.2174/0929867043456115

Affiliations: Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre, St. Andrews Place, East Melbourne, Victoria 3002, Australia

Publication date: 2004-01-01

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more